The primary aim of this study was to investigate if TREM2 p.R47H risk variant carriers have reduced in vivo microglial activation, measured using TSPO signal, compared to non-carriers also at increased risk of Alzheimer’s disease. Here, TREM2 is linked to Alzheimer disease.